OTHER INFORMATION
−Removed: During the three and nine months ended September 30, 2024, no director or officer of the Company adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
+Added: During the three months ended March 31, 2025, no director or officer of the Company adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
The Exhibit Index appearing immediately after the signature page to this Form 10-Q is incorporated herein by reference.
1 unchanged sentence
LISATA THERAPEUTICS, INC.
−Removed: November 12, 2024 By:
+Added: May 8, 2025 By:
President & Chief Executive Officer
(Principal Executive Officer)
−Removed: November 12, 2024 By:
+Added: May 8, 2025 By:
/s/ James Nisco
19 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.